

## 해외 바이오의약품 임상 현황 (2019.11.05~2019.11.11)

한국바이오의약품협회, 2019.11.12.  
출처: ClinicalTrials.gov

### ○ 미국 8건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04140539	A Clinical Study to Enable Process Validation of Commercial Grade OTL-101	Severe Combined Immunodeficiency Due to ADA Deficiency	Biological: OTL-101	Orchard Therapeutics University of California, Los Angeles	Phase 2 Phase 3
NCT04046107	Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy	Hepatitis B Virus	Biological: Cemiplimab	National Institute of Allergy and Infectious Diseases (NIAID) Regeneron Pharmaceuticals	Phase 1 Phase 2
NCT04154670	Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment	Healthy Renal Insufficiency	Biological: MGTA-145	Magenta Therapeutics, Inc.	Phase 1
NCT04152018	Study of PF??6940434 in Patients With Advanced or Metastatic Solid Tumors.	Squamous Cell Carcinoma of the Head and Neck Renal Cell Carcinoma Ovarian Cancer Gastric Cancer Esophageal Cancer Lung Squamous Cell Carcinoma Pancreatic Cancer Bile Duct Cancer Endometrial Cancer Melanoma Cancer Urothelial Cancer	Drug: PF-6940434 Drug: PF-06801591	Pfizer	Phase 1
NCT04070378	Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease	Alzheimer Disease	Drug: Daratumumab Injection	Marc L Gordon, MD Janssen Scientific Affairs, LLC Northwell Health	Phase 2
NCT03739606	Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer	Acute Biphenotypic Leukemia Acute Leukemia Chronic Myelogenous Leukemia, BCR-ABL1 Positive Hairy Cell Leukemia Interleukin-3 Receptor Subunit Alpha Positive Recurrent Acute Lymphoblastic Leukemia Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recurrent Hematologic Malignancy Recurrent Hodgkin Lymphoma Refractory Acute Lymphoblastic Leukemia Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm Refractory Hematologic Malignancy Refractory Hodgkin Lymphoma Systemic Mastocytosis	Biological: Anti-CD123/CD3 Monoclonal Antibody MGD006	City of Hope Medical Center National Cancer Institute (NCI)	Phase 2
NCT04034485	Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH	Homozygous Familial Hypercholesterolemia	Drug: LIB003 Drug: evolocumab	LIB Therapeutics LLC	Phase 3
NCT04132817	A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2-Breast Cancer That Has Spread	Breast Cancer	Drug: nivolumab Drug: ipilimumab Drug: nab-paclitaxel	Bristol-Myers Squibb	Phase 1

### ○ 일본 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04129294	Exploratory Study of NS-089/NCNP-02 in DMD	Duchenne Muscular Dystrophy	Drug: NS-089/NCNP-02	National Center of Neurology and Psychiatry, Japan Nippon Shinyaku Co., Ltd.	Phase 1 Phase 2
NCT04082429	Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors	Haemophilia A Without Inhibitors Haemophilia B Without Inhibitors	Drug: Concizumab	Novo Nordisk A/S	Phase 3

### ○ 중국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04146285	A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders	Neuromyelitis Optica Spectrum Disorders	Drug: BAT4406F	Bio-Thera Solutions	Phase 1